Tate & Lyle Ventures backs Evolve BioSystems Inc.

| Filed in:

London, August 18 2015 – Tate & Lyle Ventures announces a $2 million investment in Evolve BioSystems, Inc. a microbiome spin-out company from the University of California at Davis.

Evolve is developing revolutionary science in the field of probiotics and prebiotics for new born infants during the crucial early months of development. The investment is part of a $9 million financing round led by Horizons Ventures and follows a seed investment by Tate & Lyle Ventures in August 2014.

This investment is part of the Tate & Lyle Venture Fund which was established in 2013 to invest up to £30 million over an eight-year period in start-ups and expansion-stage companies in food sciences and enabling technologies in line with Tate & Lyle’s strategy to grow in speciality food ingredients.

Evolve was established by researchers from the University of California at Davis based on a decade of research into the developing infant microbiome and its relationship with the natural nutrients in human breast milk. Evolve has a proprietary combination of activated probiotic bacteria, prebiotics and delivery systems to provide, restore and maintain a healthy microbiome in infants during the first 6 months of life - with particular focus on those born prematurely, delivered by Caesarian section or fed exclusively with formula milk.

“Completion of the Series A round ahead of schedule is a reflection of both the importance of the ground-breaking discoveries of the Company’s founders at the University of California at Davis, and a compelling business case that focuses on the improvement of the health trajectory for babies worldwide” said Dr. David Kyle, CEO of Evolve and former founder of Martek Biosciences. “Evolve’s deep understanding of the innate balance and dietary control of a healthy infant microbiome has demonstrated the need for new pro- and prebiotic products to return these precious systems to their natural state. This investment is timely, as it will accelerate our efforts to move these new discoveries into commercial products that can improve the health outcomes for infants globally.”

The funds will be applied to support Evolve’s ongoing clinical activities, operational expansion, and preparations for commercial launch of its novel probiotic and prebiotic products, which restore the balance of the infant microbiota.

“Having originally invested in Evolve in August 2014, we are delighted to support the company as it progresses its research, clinical, and commercial endeavors” said Dr. Simon Barnes, Managing Partner of Tate and Lyle Ventures, and a member of the Board of Directors of Evolve. “Over the past year the Evolve management team has raised Seed Capital, licensed a substantial suite of intellectual property from the University of California, initiated clinical trials, and commenced business development activities for a range of products and technologies being developed by the Company”.

Simon Barnes
Managing Partner, Tate & Lyle Ventures
[email protected]

About Evolve Biosystems
Evolve Biosystems, Inc. is a privately-held microbiotics company dedicated to developing and bringing to market the next generation of products to establish, restore, and maintain a healthy human microbiome across a range of unmet clinical needs. Evolve is a spin-out from the Foods For Health Institute (FFHI) at the University of California at Davis and builds on more than a decade of research into understanding the uniqueness of the infant microbiome and its intimate interaction with breast milk components. Having led to the discovery and development of products to restore the human infant microbiome to its natural state, Evolve’s discovery platform is now being applied to solving dysbiosis issues throughout the human life cycle as well as in similar problems in production animal species. Evolve completed a seed funding round in 2014 and is undertaking multiple clinical trials to confirm the value of its proprietary prebiotic and probiotic assets in returning an infant’s microbiome to its naturally evolved state. Dr. Kyle was a founder and executive officer at Martek Biosciences, a biotechnology company similarly focused on infant nutrition which was acquired by DSM in 2010 for $1.1 B.

For more information please visit www.evolvebiosystems.com.

About Tate & Lyle Ventures
Tate & Lyle Ventures is a venture capital fund backed by Tate & Lyle PLC the global food ingredients company. Tate & Lyle Ventures invests in food sciences and nutrition opportunities globally and is currently investing its second £30 million ($45 million) fund launched in January 2013. The fund is independently managed by Circadia Ventures, an FCA authorised and regulated investment firm based in London, UK.

For more information please visit www.tateandlyleventures.com

About Horizons Ventures
Based in Hong Kong, Horizons Ventures manages the technology investments of Mr. Li Ka-Shing globally, including investments in companies such as Skype, Facebook, Spotify, Siri, Waze, Deepmind, Hampton Creek, and Windward.

For more information please visit www.horizonsventures.com

Click here for our press image gallery

About Tate & Lyle: 
Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

We have more than 3,500 employees working in around 57 locations across 39 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue from continuing operations totalled £1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on LinkedinX (Twitter)Facebook or YouTube